Tuning Reactivity of Platinum(II) Complexes
Tuning Reactivity of Platinum(II) Complexes Tuning Reactivity of Platinum(II) Complexes
17 R. A. Henderson, The Mechanism of Reactions oat Transition Metal Sites, Oxford University Press, Oxford, 1993, p. 1. 18 A. Sigel and H. Sigel, Metal ions in biological systems. Marcel Dekker Inc, New York, 1996, p 393. 19 M.L. Tobe and J. Burgess, Inorganic reaction mechanisms. Addison Wesley Longman Ltd., Essex, 1999, pp 30–43, 70–112. 20 J. D. Atwood, Inorganic and Organometallic reaction mechanisms, 2 nd Ed., Wiley- VCH Inc, New York, 1997, pp 43–61. 21 B. Rosenberg, L. Van Camp, E.B. Grimley, et al. J. Biol. Chem., 1967, 25, 1347– 1352. 22 (a) S. Hochreuther, S. T. Nandibewoor, R. Puchta, and R. van Eldik, Dalton Trans., 2012, 41, 512; (b) S. Hochreuther, R. Puchta, and R. van Eldik, Inorg. Chem., 2012, 51, 3025; (c) S. Hochreuther, R. Puchta, and R. van Eldik, Inorg. Chem., 2012, 50, 12747. 23 J. Reedijk, In: How can platinum antitumor compounds reach the cellular DNA? 226th ACS National Meeting, New York, NY, United states, September 7-11, 2003; New York, NY, United states, 2003. 24 (a) T. Soldatovic´, S. Jovanovic´, Z. D. Bugarcˇic´ and R. van Eldik, Dalton Trans., 2012, 41, 876; (b) S.J. Lippard, In: Progress in Inorganic Chemistry, Bioinorganic Chemistry, Vol. 48; John Wiley and Sons: Sydney,1995. 25 B. E. Lippert, Cisplatin: Chemistry and Biochemistry of a Leading anticancer Drug, Wiley-VCH: Zürich, 1999; (b) X. J. Lin, T. Okudua, A. Holzer and S. B. Howell, Mol. Pharmacol., 2002, 62, 1154; (c) K. S. Lovejoy, and S. J. Lippard, Dalton Trans., 2009, 48, 1065. 26 C. A. Puckett, R. J. Ernst and J. K. Barton, Dalton Trans. 2010, 39, 1159–1170. 27 C. W. Schwietert and J. P. McCue, Coord. Chem. Rev., 1990, 184, 67. 28 A. L. Harris, X. Yang, A. Hegmans, L. Povirk, J. J. Ryan, L. Kelland and N. P. Farrell, Inorg. Chem., 2005, 44, 9598. 29 (a) J. Reedijk, Chem. Commun., 1996, 801; (b) G. McGowan, S. Parsons and P. J. Sadler, Inorg. Chem., 2005, 44, 7459. 30 S. E. Miller and D. A. House, Inorg. Chim. Acta, 1989, 166, 189. 21
31 M. Kotowski and R. Van Eldik, In: Van Eldik R (Ed) Inorganic high pressure chemistry, kinetics and mechanism, Elsevier, Amsterdam, 1986, Chapters 1, 3 and 4. 32 S. J. Berners-Price, T. A. Frenkiel, U. Frey, J. D. Ranford and P. J. Sadler, J. Chem. Soc., Chem. Commun., 1992, 789. 33 C. Avendaño and J. Carlos Menéndez, Medicinal Chemistry of Anticancer Drugs, 2008, p 170 (Access online via Elsevier on 24-07-2012). 34 M. Mikola, K. D. Klika, A. Hakala and J. Arpalahti, Inorg. Chem., 1999, 38, 571. 35 V. M. Gonzalez, M. A. Fuertes, C. Alonso and J. M. Perez, Molecular Pharmacol., 2001, 59: 657. 36 (a) M. Kartalou, J. and M Essigman, Mutat. Res., 2001, 478, 1; (b) A. M. J. Fichtinger-Schepman, J. L. van der Veer, J. H. J. den Hartog, P. H. M. Lohnman and J. Reedijk, Biochem., 1985, 24, 707. 37 M. A. Fuertes, C. Alonso and J. M. Pérez, Chem. Rev., 2003, 103, 645. 38 Z. Guo, P. J. Sadler, and E. Zang, Chem. Commun.,1997, 1,27. 39 A. Pullman, B. Q. Pullman, Rev. Biophys. 1983, 14, 289–298. 40 E. R. Jamieson and S. J. Lippard, Chemistry Reviews 1999, 99, 2467-2498. 41 (http://bio.chem.niu.edu/Resources/fall2000 /Templates/DNA%20and%20cisplatin/adducts.htm; Siddik, 2003) accessed on 12/07/2012. 42 H. Sigel, (Ed.), Metal ions in Biological Systems: Metal Complexes as Anticancer Agents, Marcel Dekker, 1980, 11, p. 9, 64-90, 134. 43 J. M. Teuben, M. Rodriguez, I. Zubiri and J. Reedijk, Dalton, 2000, 369-372. 44 (a) Y. W. Jung, S. J. Lippard, Chem. Rev. 2007, 107, 1387–1407; (b) U. M. Ohndorf, M. A. Rould, Q. He, C. O. Pabo, S. J. Lippard, Nature 1999, 399, 708–712; (c) Galanski, M.; Keppler, B. K. Anticancer Agents Med. Chem. 2007, 7, 55. 45 L. M. Pasetto, M. A. D’Andrea, A. A. Brandes, E. Rossi, S. Monfardini, Critic. Rev., Onco. / Hemat., 2006, 59. 46 (a) J. Reedijk, Chem. Rev., 1999, 99, 2499; (b) J. Reedijk, PNAS., 2003, 100, 3611. (c) J. H. J. den Hartog, C. Altona, J. H. van Boom, G. A. van der Marel, C. A. G. Haasnoot, J. Reedijk, J. Biomol. Struct. Dyn., 1985, 2, 1137. (d) J. H. J. den Hartog, C. 22
- Page 1 and 2: Tuning Reactivity of Platinum(II) C
- Page 3 and 4: Declaration This thesis report is b
- Page 5 and 6: Abstract Systematic kinetic and the
- Page 7 and 8: Table of contents Acknowledgements
- Page 9 and 10: 2.5.5 Effect of Non-participating G
- Page 11 and 12: 5.2.1 Chemical and Solutions ......
- Page 13 and 14: 7.2 Experimental Section ..........
- Page 15 and 16: procurements, Messers P. Forder and
- Page 17 and 18: Figure 2.2 Potential energy profile
- Page 19 and 20: Figure 4.6 Concentration dependence
- Page 21 and 22: Figure 6.1 Spectrophotometric titra
- Page 23 and 24: List of Tables Table 2.1 A selectio
- Page 25 and 26: Table 6.4 Summary of rate constants
- Page 27 and 28: TU thiourea DMTU 1,3-dimethyl-2-thi
- Page 30 and 31: Table of Contents-1 Chapter 1 .....
- Page 32 and 33: 1.0 Introduction 1.1 Cancer Disease
- Page 34 and 35: toxic potential. The most well-know
- Page 36 and 37: 1.3.2.2 Cellular Uptake Cisplatin i
- Page 38 and 39: H 3N OH 2 Pt H 3N OH 2 Active Pt(II
- Page 40 and 41: transformational pathways that comp
- Page 42 and 43: the hydrolysis of the complex, wher
- Page 44 and 45: 1.3.4 Terpyridine Platinum(II) Comp
- Page 46 and 47: H 3 N Cl Pt NH 3 H 3 N NH 2 (CH 2 )
- Page 48 and 49: 1.4 Kinetic Interest The platinum-b
- Page 50 and 51: 3. The effect of varying the positi
- Page 54 and 55: Altona J. H. van Boom, G. A. van de
- Page 56 and 57: 76 (a)J. Kašpárková, J. Zehnulov
- Page 58 and 59: Table of Contents-2 Chapter Two ...
- Page 60 and 61: List of Tables Table 2.1: A selecti
- Page 62 and 63: The mononuclear Pt(II) complexes 1-
- Page 64 and 65: Potential Energy R + X RX 1 transit
- Page 66 and 67: For the associative mechanism (A),
- Page 68 and 69: the concentration of one of the rea
- Page 70 and 71: k obs , s -1 0.00030 0.00025 0.0002
- Page 72 and 73: k = Ae -Ea/RT 2.14 lnk = lnA - E a
- Page 74 and 75: = 23.76 + R Hence, a plot of ln ⎛
- Page 76 and 77: iii. # Δ V ≈ 10 cm3 mol-1 featur
- Page 78 and 79: conventional methods are classical
- Page 80 and 81: Figure 2.6: Schematic diagram of a
- Page 82 and 83: The light transmitted from the samp
- Page 84 and 85: c. Oxidizability: Ligands that are
- Page 86 and 87: Table 2.1: A selection of n o pt va
- Page 88 and 89: eaction with different nucleophiles
- Page 90 and 91: eaction site from direct attack by
- Page 92 and 93: PEt 3 PEt 3 R PEt 3 Pt Pt Y Y Cl R
- Page 94 and 95: direct displacement of the leaving
- Page 96 and 97: therefore, weaken the bond of the l
- Page 98 and 99: σ-Donation According to classical
- Page 100 and 101: References 1 (a) J. Reedijk, Chem.
31 M. Kotowski and R. Van Eldik, In: Van Eldik R (Ed) Inorganic high pressure<br />
chemistry, kinetics and mechanism, Elsevier, Amsterdam, 1986, Chapters 1, 3 and<br />
4.<br />
32 S. J. Berners-Price, T. A. Frenkiel, U. Frey, J. D. Ranford and P. J. Sadler, J. Chem.<br />
Soc., Chem. Commun., 1992, 789.<br />
33 C. Avendaño and J. Carlos Menéndez, Medicinal Chemistry <strong>of</strong> Anticancer Drugs,<br />
2008, p 170 (Access online via Elsevier on 24-07-2012).<br />
34 M. Mikola, K. D. Klika, A. Hakala and J. Arpalahti, Inorg. Chem., 1999, 38, 571.<br />
35 V. M. Gonzalez, M. A. Fuertes, C. Alonso and J. M. Perez, Molecular Pharmacol.,<br />
2001, 59: 657.<br />
36 (a) M. Kartalou, J. and M Essigman, Mutat. Res., 2001, 478, 1; (b) A. M. J.<br />
Fichtinger-Schepman, J. L. van der Veer, J. H. J. den Hartog, P. H. M. Lohnman and<br />
J. Reedijk, Biochem., 1985, 24, 707.<br />
37 M. A. Fuertes, C. Alonso and J. M. Pérez, Chem. Rev., 2003, 103, 645.<br />
38 Z. Guo, P. J. Sadler, and E. Zang, Chem. Commun.,1997, 1,27.<br />
39 A. Pullman, B. Q. Pullman, Rev. Biophys. 1983, 14, 289–298.<br />
40 E. R. Jamieson and S. J. Lippard, Chemistry Reviews 1999, 99, 2467-2498.<br />
41 (http://bio.chem.niu.edu/Resources/fall2000<br />
/Templates/DNA%20and%20cisplatin/adducts.htm; Siddik, 2003) accessed on<br />
12/07/2012.<br />
42 H. Sigel, (Ed.), Metal ions in Biological Systems: Metal <strong>Complexes</strong> as Anticancer<br />
Agents, Marcel Dekker, 1980, 11, p. 9, 64-90, 134.<br />
43 J. M. Teuben, M. Rodriguez, I. Zubiri and J. Reedijk, Dalton, 2000, 369-372.<br />
44 (a) Y. W. Jung, S. J. Lippard, Chem. Rev. 2007, 107, 1387–1407; (b) U. M. Ohndorf,<br />
M. A. Rould, Q. He, C. O. Pabo, S. J. Lippard, Nature 1999, 399, 708–712; (c)<br />
Galanski, M.; Keppler, B. K. Anticancer Agents Med. Chem. 2007, 7, 55.<br />
45 L. M. Pasetto, M. A. D’Andrea, A. A. Brandes, E. Rossi, S. Monfardini, Critic. Rev.,<br />
Onco. / Hemat., 2006, 59.<br />
46 (a) J. Reedijk, Chem. Rev., 1999, 99, 2499; (b) J. Reedijk, PNAS., 2003, 100, 3611.<br />
(c) J. H. J. den Hartog, C. Altona, J. H. van Boom, G. A. van der Marel, C. A. G.<br />
Haasnoot, J. Reedijk, J. Biomol. Struct. Dyn., 1985, 2, 1137. (d) J. H. J. den Hartog, C.<br />
22
Change language